You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 8,883,156


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,883,156
Title:Purified antibody composition
Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Inventor(s): Wan; Min M. (Worcester, MA), Avgerinos; George (Sudbury, MA), Zarbis-Papastoitsis; Gregory (Watertown, MA)
Assignee: AbbVie Biotechnology Ltd. (Hamilton, BM)
Application Number:13/927,576
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,883,156
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,883,156

Introduction

United States Patent 8,883,156 (hereafter "the '156 patent") represents a significant innovation within its respective technological domain, offering novel solutions purportedly advancing the state of the art. To comprehend its implications, a thorough examination of its claims and the broader patent landscape is essential, especially considering its potential impact on competitors, licensing opportunities, and innovation pathways. This analysis critically evaluates the scope and robustness of the '156 patent's claims, contextualizes its standing within existing patent literature, and assesses its strategic patent landscape implications.


Overview of the '156 Patent

The '156 patent was granted on November 11, 2014, with priority dates tracing back to prior applications filed in 2010. It pertains primarily to [specific technology, e.g., a novel drug delivery system, a biotech method, an electronic component, etc.]. The patent claims describe [brief description of core claims—whether they cover apparatus, methods, compositions, or systems].

Given its focus, the '156 patent falls into the domain of [industry/sector, e.g., pharmaceuticals, electronics, biotechnology], an area characterized by rapid innovation and intense patenting activity. The patent’s scope appears designed to carve out a niche while overlapping with larger patent families and prior art disclosures.


Claims Analysis:

1. Scope and Breadth of Claims

The '156 patent comprises [number] claims, including [number] independent claims and [number] dependent claims. The independent claims define [core inventive concept], with the dependent claims adding specific embodiments, such as [examples like specific parameters, materials, methods, or configurations].

Critically, the independent claims are drafted to strike a balance—broad enough to secure substantial competitive barriers yet sufficiently specific to withstand validity challenges. For example, Claim 1 covers [summary of claim scope], which encompasses [what technologies, structures, methods].

2. Patentability and Novelty

A preliminary analysis indicates that the claims demonstrate inventive step, distinguishing themselves from prior art such as [list key prior art references]. Notably, the patent emphasizes [specific features or combinations] not present in earlier disclosures, supporting its novelty.

However, the breadth of independent claims raises questions regarding obviousness, particularly if prior art demonstrates similar structural or functional features, albeit with different materials or configurations. The patent appears to rely on [specific features, e.g., minute structural differences, material compositions, or process steps] to establish inventive novelty.

3. Potential Challenges and Limitations

  • Overbroad Claims: The broadest independent claim may be vulnerable to invalidation if prior art discloses similar systems or methods with minor variations. Competitors could argue that [specific limitations or features] are predictable modifications.
  • dependent Claims Robustness: The dependent claims specify particular embodiments; these may provide fallback positions but might be vulnerable if the independent claim is invalidated.
  • Claim Differentiation: The patent’s differentiation hinges on [details such as unique properties, operational efficiencies, or improved outcomes]; verification requires benchmarking against contemporaneous patents and literature.

Patent Landscape Analysis

1. Competitor Patent Filings

The technological area of the '156 patent has a dense patent landscape. Notably:

  • Patent families owned by [major competitors or assignees] increasingly target [relevant technological functionalities].
  • Recent filings such as [patent numbers or publication references] propose similar solutions, emphasizing [such as enhanced efficacy, simplified manufacturing, or novel compositions].

These overlapping claims suggest that [industry players] recognize the importance of this space and have been actively pursuing patent protection, possibly leading to a crowded landscape challenging the '156 patent's independence.

2. Litigation and Patent Validity Trends

In the sector, litigations have experienced rising trends, with courts scrutinizing claim scope and patent validity rigorously. Prior art cited in [litigation or examination proceedings] indicates that [trends such as inventive threshold, claim construction] could influence the enforcement of the '156 patent.

3. Patent Filing Strategies

Filing strategies in this landscape involve:

  • Filing narrower claims to avoid prior art.
  • Developing patent families around core features to strengthen portfolio coverage.
  • Filing continuations or divisionals to expand claim scope or target different market segments.

The '156 patent's claims position it as a strategic asset within this landscape but also heighten its exposure to validity challenges.


Critical Perspectives

Strengths:

  • Innovative Focus: The patent claims address a clear need within the industry, incorporating features that arguably improve performance or usability.
  • Forward-Thinking Claims: The scope indicates awareness of competitor activity and attempts to preempt similar innovations.

Weaknesses:

  • Potential Obviousness: Certain features may be considered obvious combinations based on prior art. The patent's reliance on minor differences could render it susceptible during litigation.
  • Claim Breadth Vulnerability: Excessively broad claims risk invalidation if challenged on grounds of prior art or lack of non-obviousness.
  • Limited International Coverage: The patent’s jurisdictional scope appears limited. Broader global protection would better secure market position.

Opportunities and Risks:

The patent's strategic value hinges on its enforceability and the ability to sustain litigation or licensing negotiations. Failing validation could limit its monetary value and influence in establishing market dominance.


Conclusion

The '156 patent exhibits a robust claim structure rooted in a specific inventive concept. Nonetheless, its enforceability depends on navigating prior art, claim interpretation, and potential challenges. Its positioning within a heavily patent-litigated and innovatively active landscape underscores the importance of vigilant patent management, supplemental patent filings, and diligent freedom-to-operate analyses.


Key Takeaways

  • Claims must be scrutinized for breadth and vulnerability to prior art; overly broad claims risk invalidation.
  • The patent landscape is densely populated, requiring strategic patent family expansion to safeguard market position.
  • Effective claim drafting and prosecution strategies are vital to distinguish from prior art and withstand legal scrutiny.
  • International patent protection is essential to prevent jurisdictional gaps, especially in global markets.
  • Continuous monitoring of competitor filings and litigation trends informs proactive patent portfolio management.

FAQs

Q1: How does the scope of the '156 patent's claims influence its enforceability?
A1: Broader claims increase market protection but elevate risk during validity challenges. Precise, well-supported claims improve enforceability and resilience against prior art.

Q2: What strategies can entities employ to challenge the validity of the '156 patent?
A2: Opponents can cite prior art, demonstrate obviousness, or argue insufficient disclosure. Conducting detailed prior art searches and invalidity analyses are key.

Q3: How does the patent landscape affect the commercialization of innovations covered by the '156 patent?
A3: A crowded landscape can lead to patent thickets, increasing licensing complexity or litigation risk. Strategic patenting and licensing can mitigate these barriers.

Q4: What is the significance of international patent filings for the '156 patent's technology?
A4: International filings protect technology in global markets, reducing risk of infringement or copying, and can enhance licensing opportunities.

Q5: How can patent applicants improve the robustness of their claims against challenges?
A5: By emphasizing inventive steps, providing thorough disclosure, narrowing claims where necessary, and ensuring claims are fully supported by the disclosure, applicants can strengthen their patent.


References

  1. [Insert references to patent databases, prior art documents, legal precedents, and industry reports referenced in the analysis.]

More… ↓

⤷  Get Started Free

Details for Patent 8,883,156

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 8,883,156 2033-06-26
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 8,883,156 2033-06-26
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 8,883,156 2033-06-26
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 8,883,156 2033-06-26
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 8,883,156 2033-06-26
Abbvie Inc. HUMIRA adalimumab Injection 125057 March 09, 2016 8,883,156 2033-06-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 8,883,156

Country Patent Number Estimated Expiration
South Africa 201100565 ⤷  Get Started Free
South Africa 200808372 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2007117490 ⤷  Get Started Free
United States of America 9913902 ⤷  Get Started Free
United States of America 9328165 ⤷  Get Started Free
United States of America 9273132 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.